Nausea News and Research

RSS
Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.
Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Tips for pregnant women during summer

Tips for pregnant women during summer

Eli Lilly, Synthes collaborate to develop osteoinductive products

Eli Lilly, Synthes collaborate to develop osteoinductive products

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

More women than men are unnecessarily referred for nuclear stress tests

More women than men are unnecessarily referred for nuclear stress tests

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium reports results from two VELCADE based combination studies against multiple myeloma

MSU professor to lead acetazolamide clinical trial on idiopathic intracranial hypertension

MSU professor to lead acetazolamide clinical trial on idiopathic intracranial hypertension

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

Geron's GRNOPC1 Phase 1 trial results on spinal cord injury presented at international conferences

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Ovarian cancer screenings do not reduce risk of death

Ovarian cancer screenings do not reduce risk of death

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.